HTG Molecular Appoints Dr. Joseph Sparano as Lead of Its Clinical Scientific Advisory Board for Breast Cancer Program

TUCSON, Ariz. , Jan. 23, 2019 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has appointed Dr. Joseph Sparano as lead of its Breast Cancer Program Scientific Advisory Board (SAB).